Group items tagged

The Medicines and Healthcare products Regulatory Agency (MHRA) has approved a new indication of semaglutide (Wegovy), authorising its use to reduce the risk of serious heart problems and strokes in adults who are obese or overweight. Semaglutide, a GLP-1 receptor agonist, was previously approved for use in the treatment of obesity and weight management, to be used alongside diet, physical activity and behavioural support. The latest approval establishes it as the first weight loss drug to be prescribed to prevent cardiovascular events, such as cardiovascular death, non-fatal heart attack and non-fatal stroke, in people with established cardiovascular disease and a Body Mass Index (BMI) higher or equal to 27 kg/m2. Novo Nordisk, the manufacturer of Wegovy, received this authorisation on 23 July following compelling evidence from a recent post-approval clinical study involving over 17,600 participants. The study demonstrated that Wegovy, administered at a dose of 2.4 mg once weekly via subcutaneous injection for up to five years, significantly lowers the incidence of major adverse cardiovascular events (MACE) by 20 per cent compared to a placebo.

As Know Your Numbers! Week (2-8 September) kicks off, the NHS England is encouraging people in the East Midlands to get their blood pressure checked to prevent heart attacks and strokes. The residents can get their blood pressure checked at several places, including their local pharmacies. The initiative, part of a global campaign, highlights the crucial role of monitoring blood pressure, especially for those aged 40 and over. It is recommended that all adults aged 40 or over have their blood pressure tested at least every five years. High blood pressure or hypertension affects about a third of adults in the UK and is a major risk factor for cardiovascular disease (CVD), which is one of the leading causes of death in England. This condition often has no noticeable symptoms, but if untreated, it can result in serious health problems such as heart attacks and strokes. Local pharmacies play a crucial role in this health campaign, enabling individuals to monitor their risk of cardiovascular disease without needing an appointment. The NHS community pharmacy blood pressure check service has delivered more than a million checks nationally in the past year.

Diabetes is recognised as a major cause of blindness, kidney failure, heart attacks, stroke and lower limb amputation. According to World Health Oragnization (WHO), more than 95 per cent of people with diabetes have type 2 diabetes, which is often preventable. In the UK, there are over 3 million cases of diabetes and a staggering 10 per cent of the NHS budget is spent on diabetes, with 90 per cent of this allocated to treating type 2 diabetes. Kavita Sharma, a clinical pharmacist specialising in diabetes and founder of Desi Diabetes, warns that the number of type 2 diabetes diagnoses is increasing each year, along with the rising prevalence of pre-diabetes. The pharmacist highlights that type 2 diabetes can be prevented through lifestyle changes, such as adopting a healthy diet, maintaining a healthy weight, and incorporating regular physical activity into daily life.

A new report from the Company Chemists' Association (CCA) is calling on NHS England to commission a community pharmacy-based national Type 2 diabetes screening service, which could save the NHS £50m each year. The CCA report, titled 'Increasing Access to Diabetes Screening and Prevention Through Community Pharmacy', highlights the urgent need for a national patient pathway for diabetes detection and management. It outlines how NHS-commissioned diabetes screening in community pharmacies across England could deliver numerous health benefits each year, including: Screening 1.5 million adults and identifying 180,000 prediabetics; Detecting 45,000 undiagnosed cases of diabetes and preventing them from developing serious complications Preventing nearly 7,000 heart attacks and strokes, and thus improving patients' quality of life Avoiding severe sight loss in around 15,000 people over their lifetime Saving the NHS £50 million annually by reducing diabetes-related costs. Type 2 diabetes and its complications are currently estimated to account for 10 per cent of the NHS annual budget, and this figure is projected to rise to 17 per cent by 2035/36.

The journey for patients to quit smoking can be challenging, but with the right strategies and support, it is achievable. Smoking cessation is a critical step for patients towards improving overall health and well-being. We caught up with Thorrun Govind, pharmacist, TV health expert and pharmacy lawyer at Brabners for her top tips. Govind notes that smoking is a leading cause of preventable diseases and deaths worldwide. It is associated with numerous health issues, including lung cancer, heart disease, stroke, and chronic obstructive pulmonary disease (COPD). Quitting smoking can significantly reduce the risk of these conditions and improve quality of life. Within weeks of quitting, individuals often experience improved lung function, better circulation, and enhanced sense of taste and smell. Govind advises that; After 20 minutes of quitting your pulse rate, will already be starting to return to normal. After 48 hours of quitting your carbon monoxide levels have dropped to that of a non-smoker. Your lungs are clearing out mucus and your senses of taste and smell are improving. After 1 year your risk of heart attack will have halved compared with a smoker's. This piece explores the various methods and benefits of smoking cessation.